EGFR Exon 20 Mutations in NSCLC

Thoracic oncologists evaluate emerging data presented at the ASCO 2020 virtual meeting on agents for the treatment of EGFR exon 20 mutations.

Data from the following clinical trials are discussed:

  • ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. (Piotrowska Z et al. 2020 ASCO annual meeting. Abstract 9513.)

  • Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. (Le X at al. 2020 ASCO annual meeting. Abstract 9514.)

  • Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)

Related Videos
Henry S. Park, MD, MPH
Expert on lung cancer
Expert on lung cancer
Anne Chiang, MD, PhD
Sarah Goldberg, MD, MPH
Ferdinandos Skoulidis, MD, PhD, MRCP
Amy L. Cummings, MD, PhD
Expert on lung cancer
Related Content